K-V Pharmaceutical Co - FORM 10-K - EX-23.2 - CONSENT OF KPMG LLP - December 23, 2010

Attached files

file filename
10-K - FORM 10-K - K-V Pharmaceutical Cod10k.htm
EX-4.7 - PLEDGE AND SECURITY AGREEMENT - K-V Pharmaceutical Codex47.htm
EX-4.8 - PROMISSORY NOTE - K-V Pharmaceutical Codex48.htm
EX-4.9 - PROMISSORY NOTE - K-V Pharmaceutical Codex49.htm
EX-4.6 - CREDIT AND GUARANTY AGREEMENT - K-V Pharmaceutical Codex46.htm
EX-4.12 - REGISTRATION RIGHTS AGREEMENT - K-V Pharmaceutical Codex412.htm
EX-4.10 - STOCK PURCHASE WARRANT CERTIFICATE NO. W-1 - K-V Pharmaceutical Codex410.htm
EX-4.11 - STOCK PURCHASE WARRANT CERTIFICATE NO. W-2 - K-V Pharmaceutical Codex411.htm
EX-21 - LIST OF SUBSIDIARIES - K-V Pharmaceutical Codex21.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 - K-V Pharmaceutical Codex321.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - K-V Pharmaceutical Codex311.htm
EX-23.1 - CONSENT OF BDO USA LLP - K-V Pharmaceutical Codex231.htm
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 - K-V Pharmaceutical Codex322.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - K-V Pharmaceutical Codex312.htm
EX-10.31 - EMPLOYMENT AGREEMENT BETWEEN COMPANY AND THOMAS S. MCHUGH - K-V Pharmaceutical Codex1031.htm
EX-10.4 - K-V PHARMACEUTICAL COMPANY FIFTH RESTATED PROFIT SHARING PLAN & TRUST AGREEMENT - K-V Pharmaceutical Codex104.htm

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

The Board of Directors

K-V Pharmaceutical Company:

We consent to the incorporation by reference in the registration statements (Nos. 33-44927, 333-00199, 333-48252, and 333-85516) on Form S-8 and the registration statements (Nos. 333-87402 and 333-106294) on Form S-3 of K-V Pharmaceutical Company (the Company) of our report dated March 25, 2010, with respect to the consolidated balance sheet of K-V Pharmaceutical Company and subsidiaries as of March 31, 2009, and the related consolidated statements of operations, comprehensive income (loss), shareholders’ equity, and cash flows for each of the years in the two-year period ended March 31, 2009, and the related financial statement schedule for each of the years in the two-year period ended March 31, 2009, which report appears in the March 31, 2010 annual report on Form 10-K of the Company.

Our report dated March 25, 2010 on the consolidated financial statements contains an explanatory paragraph that states the Company has suspended the shipment of all products manufactured by the Company and must comply with a consent decree with the FDA before approved products can be reintroduced to the market. Significant negative impacts on operating results and cash flows from these actions including the potential inability of the Company to raise capital; suspension of manufacturing; significant uncertainties related to litigation and governmental inquiries; and debt covenant violations raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements and financial statement schedule do not include any adjustments that might result from the outcome of that uncertainty.

(signed)

/s/ KPMG LLP

St. Louis, Missouri

December 23, 2010

K-V Pharmaceutical Co Reports

Also read